Cannabidiol

Cannabidiol (CBD) is a naturally occurring, non-intoxicating phytocannabinoid — a small-molecule chemical compound isolated from Cannabis sativa. Unlike tetrahydrocannabinol (THC), it does not produce euphoria, which has made it attractive as a therapeutic agent. It is a lipophilic, poorly water-soluble molecule, and this physicochemical profile is central to both its pharmacology and the practical challenges of formulating it for clinical use.

CBD is studied as a pleiotropic bioactive with reported anti-inflammatory, neuroprotective, and analgesic activity, and it has been investigated across a wide range of conditions including neuropathic pain, hyperglycemia and its vascular complications, HIV-associated neurocognitive impairment, and osteoarthritis. Its effects are attributed to modulation of the endocannabinoid system together with actions on inflammatory signaling rather than to a single molecular target. A dominant theme in the current literature is CBD's poor oral bioavailability — on the order of a few percent — driven by low aqueous solubility and extensive first-pass metabolism. This has motivated extensive delivery and formulation research, including self-nanoemulsifying systems, nanostructured lipid carriers, amorphous phospholipid dispersions, and microfluidic nanoparticles, as well as co-delivery strategies pairing CBD with absorption enhancers such as piperine or with complementary bioactives like hesperetin and apigenin. Full-spectrum cannabis preparations combining CBD with THC have likewise been explored, for example as perioperative sedatives in veterinary surgery.